Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

Berk,M, Ichim,C and Brook,S 2001, Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study., International Clinical Psychopharmacology, vol. 16, no. 2, pp. 87-92.

Attached Files
Name Description MIMEType Size Downloads

Title Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Author(s) Berk,MORCID iD for Berk,M orcid.org/0000-0002-5554-6946
Ichim,C
Brook,S
Journal name International Clinical Psychopharmacology
Volume number 16
Issue number 2
Start page 87
End page 92
Publisher Lippincott, Williams & Wilkins
Place of publication England
Publication date 2001-03
ISSN 0268-1315
Keyword(s) Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Psychiatry
PSYCHIATRY, SCI
mirtazapine
negative symptoms
ANTIPSYCHOTIC-DRUGS
INDUCED CATALEPSY
FLUOXETINE
CLOZAPINE
AUGMENTATION
RECEPTORS
PROLACTIN
RATS
Summary The negative symptoms of schizophrenia remain a major clinical challenge. Mirtazapine is an antidepressant with antagonist properties at 5-HT2A, 5-HT3 and alpha 2 receptors as well as indirect 5-HT1a agonist effects. Many of these pharmacological actions have clinical or preclinical evidence of efficacy in schizophrenia. This study was a 6-week randomized placebo-controlled trial of mirtzepine or placebo add on to haloperidol 5 mg in the treatment of 30 patients with DSM-IV schizophrenia. The primary finding of the trial was a 42% reduction in Positive and Negative Syndrome Scale (PANSS) negative symptom scores in the mirtazapine group compared to placebo at the end of 6 weeks (mirtazapine 13.9, SD 1.56; placebo 23.9, SD 1.56; P = 0.000, F = 20.31, d.f. = 1). The PANNS total scores, Clinical Global Impression severity and improvement scales in addition showed superiority of mirtazapine over placebo. There was no difference between the groups on the Hamilton depression scale at endpoint, suggesting that the improvement in negative symptoms was not an artifact of mood improvement. These results suggest a potential role for mirtazapine in the negative symptoms of schizophrenia.
Language eng
Field of Research 0 Not Applicable
Socio Economic Objective 0 Not Applicable
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2001, Lippincott, Williams & Wilkins
Persistent URL http://hdl.handle.net/10536/DRO/DU:30071308

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 67 times in TR Web of Science
Scopus Citation Count Cited 73 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 340 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Wed, 18 Mar 2015, 10:13:19 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.